mufa 22:1 n-11

MUFA 22:1 n‑11, more commonly known as cetoleic acid, is a long‑chain monounsaturated fatty acid characterized by a 22‑carbon chain and a single double bond located at the eleventh carbon from the methyl end. Chemically classified as cis‑11‑docosenoic acid, this fatty acid belongs to the omega‑11 class of fatty acids, which are relatively uncommon in typical human diets compared with omega‑9 or omega‑3 fatty acids. Unlike essential fatty acids such as alpha‑linolenic acid (an omega‑3) or linoleic acid (an omega‑6), there are no established dietary reference intakes specifically for cetoleic acid in humans. Instead, its nutritional significance is considered within the context of total monounsaturated fatty acid (MUFA) intake, which is widely recognized for its positive role in heart health and metabolic regulation when it replaces saturated fats in the diet. Cetoleic acid occurs naturally in some animal sources, particularly marine oils such as herring and cod liver oil, where concentrations may reach up to about 12% of total fatty acids. It is also present in the wax esters of jojoba oil and in certain plant oils such as those from the Chilean hazelnut (Gevuina avellana). The intake of cetoleic acid in most human diets is typically low relative to that of more abundant MUFAs like oleic acid, which is the dominant MUFA found in olive oil, canola oil, and many nuts and seeds. While the biological role of cetoleic acid in humans remains under investigation, research in cell culture and animal models suggests it may modulate fatty acid metabolism, including enhancing the conversion of shorter‑chain fatty acids like alpha‑linolenic acid into longer‑chain omega‑3 fatty acids such as EPA and DHA. Despite interest in its metabolic effects, clinical evidence directly linking cetoleic acid intake to specific health outcomes in humans is currently limited.

The primary recognized functions of cetoleic acid (MUFA 22:1 n‑11) are as a component of cellular lipids and as a source of energy. Like other fatty acids incorporated into triglycerides and phospholipids, cetoleic acid contributes to the structural integrity and fluidity of cell membranes. Its presence in marine oils and certain plant fats indicates an ecological role in lipid metabolism, though the specific functional roles in humans remain an emerging area of research. Laboratory studies suggest that cetoleic acid may influence fatty acid metabolism beyond serving as an energy source. For example, in vitro research using human hepatocyte cell lines and primary hepatocytes from fish indicates that higher levels of cetoleic acid can stimulate the synthesis of long‑chain omega‑3 fatty acids such as EPA and DHA from their precursor alpha‑linolenic acid. This suggests a possible modulatory effect on peroxisomal β‑oxidation pathways, potentially enhancing the metabolic conversion of fatty acid substrates and improving retention of beneficial long‑chain omega‑3s in tissues. Beyond its metabolic effects, cetoleic acid is classified within the broader category of monounsaturated fatty acids (MUFAs), a group of fats extensively studied for their positive effects on cardiovascular health when they replace saturated fats in the diet. Systematic reviews and dietary guidelines highlight that dietary patterns rich in MUFAs are associated with improvements in blood lipid profiles, including modest increases in HDL cholesterol and reductions in triglycerides, though specific benefits of individual MUFAs can vary. Replacing saturated fats with MUFAs has been shown to decrease intermediate markers related to cardiovascular disease and type 2 diabetes risk, improve insulin responsiveness in individuals with metabolic syndrome or diabetes, and support overall metabolic health. The Mediterranean diet, rich in olive oil, nuts, and seeds—major sources of MUFAs—has been linked to reduced incidence of heart disease, improved glycemic control, and lower systemic inflammation. Although most research has focused on oleic acid, these findings provide context for understanding the potential role of MUFA classes, including long‑chain forms like cetoleic acid. It’s critical to note that while cetoleic acid itself has not been directly studied in large human trials for specific health outcomes, its presence in healthful dietary fats aligns with evidence supporting diets high in unsaturated fats for cardiovascular and metabolic health. Future research may clarify whether cetoleic acid confers unique benefits beyond those attributed to total MUFA intake.

Currently, there are no established dietary reference intakes (DRIs), recommended dietary allowances (RDAs), or adequate intakes (AIs) specifically for cetoleic acid (MUFA 22:1 n‑11). Nutrient reference frameworks, such as those provided by the National Academies’ Food and Nutrition Board, set recommendations for broad nutrient categories like total fat, saturated fat, and sometimes specific fatty acids with essential roles (e.g., the omega‑3 alpha‑linolenic acid), but do not provide individual values for less common fatty acids like cetoleic acid. Instead, dietary guidance emphasizes the overall quality and composition of fats in the diet. For example, the Dietary Guidelines for Americans recommend that adults consume 20–35% of total calories from fats, with an emphasis on replacing saturated fats with monounsaturated and polyunsaturated fats to reduce cardiovascular risk. This overarching guidance implies that cetoleic acid, as a minor component of monounsaturated fats, contributes to total MUFA intake but does not require specific separate intake targets. Factors influencing how much MUFA you might consume include dietary pattern preferences, cultural foods, and individual energy needs. Diets such as the Mediterranean diet typically provide higher levels of monounsaturated fats due to increased consumption of foods like olive oil, nuts, and seeds. Within this context, cetoleic acid intake depends on the consumption of foods containing this specific fatty acid, such as certain fish oils and animal fats, which are not usually primary fat sources for most people. Rather than focusing on single fatty acids, nutrition professionals recommend ensuring that monounsaturated fats collectively are a significant part of your fat intake, displacing saturated and trans fats, to support heart health and metabolic function. Optimal intakes of total MUFAs vary depending on individual health goals and dietary needs, but there is strong consensus that dietary patterns emphasizing unsaturated fats are preferable. Until more evidence is available on the specific requirements and effects of cetoleic acid, focusing on balanced dietary sources of monounsaturated fats will ensure adequate intake of beneficial fats, including minor components like MUFA 22:1 n‑11.

Because cetoleic acid is not considered an essential nutrient in humans and does not have established intake recommendations, there are no defined deficiency symptoms attributable specifically to a lack of MUFA 22:1 n‑11. In general, the human body can synthesize most monounsaturated fatty acids de novo, and it does not rely on dietary intake of individual MUFAs for survival in the way that it relies on essential fatty acids such as linoleic acid and alpha‑linolenic acid, which must be obtained through the diet. Consequently, specific clinical signs of cetoleic acid deficiency have not been characterized in human populations. However, insufficient intake of overall healthy fats, including monounsaturated and polyunsaturated fats, in favor of diets high in saturated and trans fats, may contribute to undesirable metabolic outcomes. Diets low in unsaturated fats and high in unhealthy fats can lead to unfavorable blood lipid profiles, increased LDL cholesterol, and heightened risk of cardiovascular disease. In contrast, evidence suggests that replacing saturated fats with unsaturated fats, including MUFAs, is associated with improved blood lipid markers and reduced risk of chronic metabolic diseases. Therefore, signs that could theoretically reflect inadequate intake of monounsaturated fats as a group include elevated LDL cholesterol, suboptimal HDL cholesterol levels, and impaired insulin sensitivity. These are not specific to cetoleic acid itself but reflect broader dietary fat quality. At‑risk populations for poor fatty acid intake patterns include individuals consuming diets high in processed foods, those with limited access to foods rich in unsaturated fats, and people following restrictive diets that minimize all fats. Health professionals assess overall dietary patterns rather than individual fatty acid levels to gauge risk. Since there is no clinical biomarker or established optimal blood range for cetoleic acid specifically, deficiency is not diagnosed through laboratory testing for this fatty acid alone, and health impacts are assessed based on broader dietary fat patterns and related metabolic markers.

Specific data on cetoleic acid (MUFA 22:1 n‑11) content in foods are limited, and comprehensive USDA values for this fatty acid are not available. However, this long‑chain MUFA is found in certain animal fats and marine oils where it contributes a small proportion of total fatty acids. Notable sources include herring and cod liver oils, which have been reported to contain measurable percentages of cetoleic acid within their lipid profiles. For example, cod liver oil can contain up to approximately 12% cetoleic acid of total fatty acids, making it a relatively rich dietary source among known foods. Other potential sources include fats from pork and certain seed oils such as jojoba wax esters and avellana (Chilean hazelnut) oil. Because intake from these sources is generally low and variable, it is most practical to consider cetoleic acid intake as part of broad monounsaturated fatty acid consumption. Since specific content data are sparse, many nutrition databases do not list cetoleic acid separately. Therefore, dietitians typically recommend foods rich in monounsaturated fats broadly to contribute to total MUFA intake. Common foods high in MUFAs include olive oil, avocados, nuts (e.g., almonds, pecans, macadamia nuts), and seeds (e.g., sesame, pumpkin seeds). Animal fats such as lard and duck fat also contain significant monounsaturated fats, though not specifically quantified for cetoleic acid. By including a variety of these foods in the diet, you will obtain a spectrum of beneficial MUFAs, even if the amount of MUFA 22:1 n‑11 remains relatively low compared to more abundant MUFAs like oleic acid. Balancing food sources that supply healthy fats as part of an overall dietary pattern is key. Emphasizing plant‑based sources like olive oil and nuts alongside moderate intake of fatty fish provides a heart‑healthy intake of monounsaturated and polyunsaturated fats that aligns with dietary guidance promoting reduced cardiovascular risk.

Monounsaturated fatty acids, including cetoleic acid (MUFA 22:1 n‑11), are absorbed in the small intestine along with other dietary lipids. The process begins with emulsification by bile salts released from the gallbladder, which facilitates the formation of micelles that transport fatty acids to the intestinal mucosa. Once inside enterocytes, monounsaturated fatty acids are re‑esterified into triglycerides and packaged into chylomicrons for transport through the lymphatic system and into the bloodstream. While much research has focused on the absorption of common fatty acids such as oleic acid and essential polyunsaturated fatty acids, less is known specifically about cetoleic acid’s absorption characteristics. Nonetheless, because cetoleic acid shares structural similarities with other long‑chain MUFAs, it is assumed to follow the same pathways. Bioavailability can be influenced by several factors. The presence of dietary fiber can reduce the absorption efficiency of fats by trapping triglycerides and fatty acids within the intestinal lumen and promoting excretion. Conversely, consuming fats with other dietary components like fat‑soluble vitamins (A, D, E, K) can enhance absorption since these nutrients share micellar transport mechanisms. Additionally, emulsified fats (such as those present in whole foods or emulsified dressings) are generally absorbed more efficiently than isolated fats because they are already in a form that facilitates micelle formation. Timing relative to food intake also plays a role. Consuming fats with a meal can slow gastric emptying, which may enhance absorption efficiency by prolonging the interaction between bile acids and dietary fats. The health of the digestive system, including adequate bile production and pancreatic lipase activity, is crucial for effective fatty acid absorption. Conditions that impair fat digestion, such as pancreatic insufficiency or cholestatic liver disease, can reduce the absorption of monounsaturated fats and lead to deficiencies in essential fatty acids and fat‑soluble vitamins. While specific research on cetoleic acid’s bioavailability is limited, its behavior is presumed to align with general principles of long‑chain fatty acid absorption.

At present, there are no widely available supplements specifically designed to provide cetoleic acid (MUFA 22:1 n‑11) in isolation, nor are there established recommended doses for such a supplement. Because cetoleic acid is present mainly as a minor component of certain marine oils or seed oils, it is not marketed independently as a dietary supplement. The general concept of supplementing with monounsaturated fatty acids focuses primarily on broader categories of healthy fats rather than individual fatty acids. For example, olive oil supplements, high‑oleic sunflower oil, and certain nut oil extracts provide significant amounts of oleic acid, the most abundant MUFA in typical diets, and these products are sometimes used to augment dietary fat intake when needed. Before considering supplementation of any fatty acids, it is important to assess your overall dietary pattern. Most individuals can obtain adequate monounsaturated fats through whole foods such as olive oil, avocados, nuts, seeds, and fatty fish. These foods not only supply beneficial fats but also provide additional nutrients such as antioxidants, fiber, and micronutrients that contribute to overall health. Dietitians generally recommend focusing on dietary sources rather than isolated supplements unless specific medical conditions or dietary restrictions limit food intake. In certain clinical contexts, a healthcare provider may advise increasing intake of healthy fats to manage dyslipidemia or support metabolic health, but supplementation choices would center around established fatty acids like omega‑3s (EPA and DHA) rather than cetoleic acid. If you are considering using oil supplements to increase your intake of beneficial fats, quality and purity are important. Choose products that have been independently tested for contaminants and oxidation, and consult a healthcare professional, especially if you are taking medications or have underlying health conditions. Because cetoleic acid lacks specific clinical data on efficacy and safety as a supplement, it should not be a primary focus of supplementation without further evidence.

There are no defined tolerable upper intake levels (ULs) for cetoleic acid (MUFA 22:1 n‑11) due to the lack of evidence indicating specific toxicity at dietary levels. Unlike fatty acids with known toxic effects at high concentrations (such as erucic acid, which has prompted regulatory limits in certain oils due to potential cardiac toxicity), cetoleic acid has not been associated with well‑characterized toxicity in humans. However, limited research suggests that high concentrations of long‑chain monounsaturated fatty acids can influence lipid metabolism and cell membrane composition, though adverse outcomes directly attributable to cetoleic acid consumption have not been documented in clinical settings. In some research contexts, cetoleic acid has been studied for its potential to modulate fatty acid metabolic pathways, but these studies are experimental rather than safety assessments. In general, consuming very high amounts of any fat, including monounsaturated fats, can contribute to excess caloric intake and may lead to weight gain if not balanced with overall energy expenditure. Diets extremely high in fats can also displace other essential nutrients and destabilize lipid profiles if saturated and trans fats predominate. Therefore, dietary guidance emphasizes balanced fat intake, prioritizing unsaturated fats while keeping total fat within recommended ranges. Because cetoleic acid is typically consumed in small amounts within the context of whole foods, it is unlikely to pose toxicity concerns when eaten as part of a balanced diet. Nonetheless, given its structural similarity to other long‑chain fatty acids that have raised concerns at high doses, moderation and diversity in dietary fat sources are prudent. Individuals with specific health conditions affecting lipid metabolism should consult with healthcare providers before making significant changes to their fat intake patterns.

There are no well‑documented drug interactions specific to cetoleic acid (MUFA 22:1 n‑11) in the scientific literature. Because this fatty acid is typically consumed as part of broader categories of monounsaturated fats, clinical guidance focuses on interactions between dietary fats in general and certain medications. High intake of dietary fats can influence the absorption of fat‑soluble drugs and medications administered orally. For example, certain lipophilic medications may have altered absorption when taken with high‑fat meals, which can either enhance or delay drug uptake. However, these effects are related to the overall fat content of the meal rather than specific types of fatty acids. Fats can also influence the pharmacokinetics of medications that are highly lipophilic, including some anticoagulants, antiepileptic drugs, and lipid‑lowering agents. While monounsaturated fats like those containing cetoleic acid are generally considered heart‑healthy, individuals taking medications that require consistent dietary conditions for optimal absorption should consult their healthcare provider about timing relative to meals. Additionally, very high intake of omega‑3 fatty acids, sometimes found in fish oil supplements that may also contain minor MUFAs, can have mild blood‑thinning effects and theoretically interact with anticoagulant medications such as warfarin, clopidogrel, or aspirin, potentially increasing bleeding risk. Although this interaction is linked more directly to omega‑3s, it highlights the importance of discussing any major changes in dietary fat intake with a clinician when on such medications.

Common Forms: olive oil supplements, high‑oleic oil capsules

Typical Doses: not applicable for isolated 22:1 n‑11

When to Take: with meals containing fats

Best Form: as part of whole dietary fats

⚠️ Interactions: potential interaction with anticoagulants when high fat intake